Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Boston Scientific (Natick, Massachusetts) last month reported a “historic quarter,” saying its profit in the second quarter ended June 30 nearly tripled to $313 million, boosted by strong sales of its recently approved drug-eluting stents (DES) and favorable currency exchange rates.

Business Developments